IOP control

Aqueous angiography: Moving toward individualized IOP control
Aqueous angiography: Moving toward individualized IOP controlAqueous angiography facilitates increased understanding of aqueous humor outflow that can provide individualized treatment for IOP control.
IOP fluctuations important factor in setting patients’ target pressureWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important.
Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
Fixed-dose combination glaucoma drug provides easy, safe IOP controlOnce-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.
Should marijuana be indicated for glaucoma?
Should marijuana be indicated for glaucoma?A recent editorial in The Journal of the American Medical Association (JAMA) raised some questions about the indications for medical marijuana, which vary greatly by state.
Contact lens sensor may solve IOP accuracy dilemmasA contact lens sensor may aid in 24-hour IOP monitoring and help measure the true diurnal and nocturnal IOP.
Lens extraction should be considered for PACGLens extraction for PACG results in good long-term control of IOP, and should be considered among the armamentarium of approaches to treat PACG.
Andras Komaromy, PhD, wins Shaffer Award for research of gene therapy to control IOPFor his efforts to prove that gene therapy could one day provide lasting control of IOP in patients with glaucoma with known genetic defects, Andras M. Komáromy, PhD, DVM, was awarded the 2015 Shaffer Prize for Innovative Glaucoma Research.